カテゴリ： GlobalData, アメリカ, 企業調査

Alnylam Pharmaceuticals Inc (ALNY)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Alnylam Pharmaceuticals Inc (ALNY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012285
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：120
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Alnylam Pharmaceuticals Inc, (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines; cardiovascular and metabolic disease; and hepatic infectious disease. It also offers Alnylam 5×15 program for advancing genetically defined disease targets for the treatment of respiratory syncytial virus and liver cancer. Alnylam employs lipid nanoparticles for intravenous systemic delivery of sRNAi to right body organs and cells so that it could trigger the RNAi mechanism. The company works in partnership with Merck, Medtronic, Roche, Novartis, Biogen, Takeda, Cubist, GlaxoSmithKline, Ascletis, The Medicines Company, Kyowa Hakko Kirin, Monsanto, and Sanofi Genzyme for advancing its RNAi therapeutics. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc (ALNY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Invitae Enters into Agreement with Alnylam Pharma 14
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 15
BioXcel Enters into Agreement with Alnylam Pharma 16
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 17
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 19
Molecular Templates Enters Into Research Collaboration With Alnylam Pharma 20
Precision NanoSystems Enters Into Delivery Collaboration With Alnylam 21
AlCana Extends Co-Development Agreement With UBC And Alnylam 22
Licensing Agreements 23
Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 23
Alnylam Pharma Enters into Licensing Agreement with Isis Pharma 24
Isis Pharma Enters into Licensing Agreement with Alnylam Pharma 25
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 26
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 28
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 29
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 30
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 31
Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 33
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 34
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 35
Alnylam Pharma Enters Into Licensing Agreement With GlaxoSmithKline 36
Equity Offering 37
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 37
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 39
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 41
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 43
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 44
Alnylam Pharma Completes Private Placement Of Shares For US$185 Million 46
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 48
Acquisition 50
Alnylam Pharma Acquires Sirna Therapeutics From Merck 50
Alnylam Pharmaceuticals Inc – Key Competitors 52
Alnylam Pharmaceuticals Inc – Key Employees 53
Alnylam Pharmaceuticals Inc – Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Joint Venture 56
Recent Developments 57
Strategy And Business Planning 57
Sep 20, 2016: Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK 57
Jan 11, 2016: Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline 58
Financial Announcements 60
Aug 09, 2017: Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity 60
May 05, 2017: Alnylam Pharmaceuticals Reports First Quarter 2017 Financial Results and Highlights Recent Period Activity 62
Feb 08, 2017: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity 64
Nov 02, 2016: Alnylam Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Period Activity 67
Aug 04, 2016: Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress 70
May 02, 2016: Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress 73
Feb 11, 2016: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress 76
Corporate Communications 80
May 09, 2017: Alnylam Expands Leadership Team with Multiple Experienced Biotech Leaders 80
Jan 03, 2017: Alnylam Announces Management Change and Key Promotion 82
Sep 19, 2016: Alnylam Expands and Strengthens Management Team as it Plans for Commercialization 83
Legal and Regulatory 84
Nov 03, 2017: Silence Therapeutics: Update on litigation matters 84
Jul 03, 2017: Silence Therapeutics: Issue of claim in the UK High Courts 85
Product News 86
12/05/2016: Alnylam Presents Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) 86
11/03/2017: Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 88
11/03/2016: Alnylam to Present Phase 1/2 Results of ALN-CC5 at 58th Annual Meeting of the American Society of Hematology 90
09/24/2016: Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 91
06/11/2016: Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study 92
06/03/2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data 94
Clinical Trials 95
Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS) 95
Feb 02, 2017: Alnylam Presents New Data on Fitusiran at EAHAD 96
Dec 04, 2016: Alnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors 98
Dec 04, 2016: Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors 100
Dec 03, 2016: Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias 102
Nov 13, 2016: Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine 104
Nov 03, 2016: Alnylam to Present New Clinical Results of Fitusiran at 58th Annual Meeting of the American Society of Hematology 106
Nov 03, 2016: Alnylam to Present Phase 1 Results of ALN-AS1 at 58th Annual Meeting of the American Society of Hematology 107
Oct 10, 2016: Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) 108
Sep 07, 2016: Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias 109
Jul 25, 2016: Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders 111
Jul 25, 2016: Alnylam to Report New Clinical Results with Fitusiran at the World Federation of Hemophilia 2016 World Congress 113
Jul 01, 2016: Alnylam Reports New Results on patisiran at the XV International Symposium on Amyloidosis 114
Jun 27, 2016: Alnylam to Report New Patisiran Results at the XV International Symposium on Amyloidosis 116
Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN) 117
Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 119
Appendix 120
Methodology 120
About GlobalData 120
Contact Us 120
Disclaimer 120

List of Tables
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Alnylam Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Alnylam Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Invitae Enters into Agreement with Alnylam Pharma 14
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 15
BioXcel Enters into Agreement with Alnylam Pharma 16
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 17
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 19
Molecular Templates Enters Into Research Collaboration With Alnylam Pharma 20
Precision NanoSystems Enters Into Delivery Collaboration With Alnylam 21
AlCana Extends Co-Development Agreement With UBC And Alnylam 22
Vir Biotechnology Enters into Licensing Agreement with Alnylam Pharma 23
Alnylam Pharma Enters into Licensing Agreement with Isis Pharma 24
Isis Pharma Enters into Licensing Agreement with Alnylam Pharma 25
Medicines Company Enters Into Licensing Agreement With Alnylam Pharma To Develop And Commercialize RNAi Therapeutics Targeting PCSK9 26
Alnylam Pharma Enters Into Licensing Agreement With Arrowhead Research 28
Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharma 29
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 30
Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 31
Alnylam Pharma Enters Into Licensing Agreement With Ascletis Pharma (Hangzhou) To Develop ALN-VSP 33
Alnylam Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe Patent 34
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 35
Alnylam Pharma Enters Into Licensing Agreement With GlaxoSmithKline 36
Alnylam Pharma Raises USD805 Million in Public Offering of Shares 37
Alnylam Pharma Raises USD359.4 Million in Public Offering of Shares 39
Alnylam Pharma Raises USD518 Million in Public Offering of Shares 41
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 43
Alnylam Pharma Completes Public Offering Of Shares For US$185 Million 44
Alnylam Pharma Completes Private Placement Of Shares For US$185 Million 46
Alnylam Pharma Completes Public Offering Of Shares For US$93 Million 48
Alnylam Pharma Acquires Sirna Therapeutics From Merck 50
Alnylam Pharmaceuticals Inc, Key Competitors 52
Alnylam Pharmaceuticals Inc, Key Employees 53
Alnylam Pharmaceuticals Inc, Subsidiaries 55
Alnylam Pharmaceuticals Inc, Joint Venture 56

★海外企業調査レポート[Alnylam Pharmaceuticals Inc (ALNY)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Frisch’s Restaurants, Inc.：戦略・SWOT・企業財務分析
    Frisch's Restaurants, Inc. - Strategy, SWOT and Corporate Finance Report Summary Frisch's Restaurants, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • PanAtlantic Exploration Co：企業の戦略的SWOT分析
    PanAtlantic Exploration Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Sequa Petroleum NV：石油・ガス：M&Aディール及び事業提携情報
    Summary Sequa Petroleum NV (Sequa Petroleum) is an oil and gas company that develops, acquires, monetises, produces and finances oil and natural gas assets. The company holds assets in Kazakhstan, North Western Europe and Sub Saharan Africa. Its Kazakhstan exploration site is located in Aksai block …
  • Redington (India) Limited (REDINGTON)：企業の財務・戦略的SWOT分析
    Redington (India) Limited (REDINGTON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • QT Vascular Ltd (5I0)：医療機器：M&Aディール及び事業提携情報
    Summary QT Vascular Ltd (QT Vascular) is a medical device manufacturing company that offers developing, manufacturing and distributing of advanced therapeutic solutions for the treatment of complex vascular diseases. The company’s products include coronary products such as Chocolate PTCA Balloon Cat …
  • GeneNews Ltd (GEN)：医療機器：M&Aディール及び事業提携情報
    Summary GeneNews Ltd (GeneNews) is a provider of molecular diagnostic products. The company develops and commercializes diagnostics and personalized medicine for cancer and other chronic diseases. Its Sentinel Principle is a novel approach to identifying biomarkers of body state using blood. GeneNew …
  • University of Bristol-医療機器分野：企業M&A・提携分析
    Summary University of Bristol (UOB) is an educational service provider that offers undergraduate and postgraduate courses and research services. The university offers courses in arts, biomedical sciences, engineering, medical and veterinary sciences, dentistry, science, and social sciences and law. …
  • OcuNexus Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary OcuNexus Therapeutics Inc (OcuNexus Therapeutics) is a development stage biopharmaceutical company engaged in novel therapeutics for unmet clinical needs in ophthalmology. It has highly differentiated, lead drug candidates based upon a novel mechanism of action such as Gap Junction Channel M …
  • Cleco Corporate Holdings LLC：企業の発電所・SWOT分析2018
    Cleco Corporate Holdings LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Mirabilis Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Mirabilis Medical Inc (Mirabilis Medical) is a medical device company that develops a non-invasive therapeutic ultrasound platform for the treatment of uterine fibroids in women. The company offers platform that targets symptoms of uterine fibroids such as pain, abnormal bleeding, pregnancy …
  • PT Berau Coal Energy Tbk：企業の戦略・SWOT・財務情報
    PT Berau Coal Energy Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Berau Coal Energy Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Compania Minera Autlan SAB de CV：企業の戦略・SWOT・財務情報
    Compania Minera Autlan SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Compania Minera Autlan SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Lloyds Banking Group Plc：企業の戦略・SWOT・財務分析
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • MMI Holdings Ltd.：企業の戦略・SWOT・財務情報
    MMI Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary MMI Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Vericel Corp (VCEL)：企業の財務・戦略的SWOT分析
    Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Hindustan Unilever Limited：戦略・SWOT・企業財務分析
    Hindustan Unilever Limited - Strategy, SWOT and Corporate Finance Report Summary Hindustan Unilever Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Mustek Limited (MST)：企業の財務・戦略的SWOT分析
    Mustek Limited (MST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Clark Public Utilities：発電所・企業SWOT分析
    Clark Public Utilities – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employ …
  • Ernst & Young Global Ltd
    Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report Summary Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Insurance and Care NSW：企業の戦略的SWOT分析
    Insurance and Care NSW - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆